Tags Archives: Anticoagulation

Perfusfind S.L.

Abstract Coating strategies play a pivotal role in anticoagulation management during extracorporeal circulation. While heparin-based coatings remain the most widely used, their limited anticoagulant efficacy may lead to adverse events..

Perfusfind S.L.

Abstract Clinically significant bleeding is a common complication of extracorporeal membrane oxygenation (ECMO), with bleeding observed in upwards of 40% of patients. Bleeding is strongly associated with systemic anticoagulation, which..

Perfusfind S.L.

Abstract Objectives Clinical practice in anticoagulation management, particularly in heparin administration, monitoring, reversal and haemostasis, is known to differ significantly. To better characterize this variability, we conducted a Europe-wide survey..

Perfusfind S.L.

Abstract Objectives Clinical practice in anticoagulation management, particularly in heparin administration, monitoring, reversal and haemostasis, is known to differ significantly. To better characterize this variability, we conducted a Europe-wide survey..

Perfusfind S.L.

Abstract Introduction Regional citrate anticoagulation (RCA) is the recommended first-line strategy for continuous renal replacement therapy (CRRT) circuits. Acute kidney injury is common in patients undergoing venoarterial extracorporeal membrane oxygenation..

Perfusfind S.L.

Abstract Hemostasis depends on the coordinated interaction between platelets, coagulation factors, endothelium, and shear forces. Current point-of-care (POC) assays evaluate isolated components of haemostasis or operate under nearly static conditions,..

Perfusfind S.L.

Abstract Objective:  To evaluate whether systemic anticoagulation therapy affects the survival of adult patients receiving venovenous extracorporeal membrane oxygenation (VV-ECMO) for acute respiratory distress syndrome (ARDS). Design:  Multicenter retrospective study...

Perfusfind S.L.

Abstract The antiphospholipid syndrome (APS) is a complex autoimmune disease that causes a state of hypercoagulability that can result in recurrent venous and arterial thromboses. APS may lead to cardiac..

Perfusfind S.L.

Abstract Introduction Due to anticoagulation during Extracorporeal Membrane Oxygenation (ECMO), patients face a higher risk of bleeding. This study aimed to assess the correlation between anticoagulation assays and hemorrhage in..

Perfusfind S.L.

Abstract Background Controversies exist in anticoagulation practices in extracorporeal membrane oxygenation (ECMO). It is uncertain whether the intensity of anticoagulation affects ECMO outcomes. Objectives To conduct a meta-analysis to determine..

Perfusfind S.L.

Abstract This chapter provides an overview of heparin, including discovery, structure, mechanism of action, and principal use for anticoagulation. For over 100 years, heparin has a central role in prophylaxis..

Perfusfind S.L.

Abstract Anticoagulation is mandatory during venoarterial extracorporeal membrane oxygenation (V-A ECMO) flow reduction trials with very low blood flow. Anticoagulation in the ECMO circuit might be intensified with less effect..

Perfusfind S.L.

Abstract Purpose of review  To provide an updated overview of hemostatic disturbances and anticoagulation management during extracorporeal membrane oxygenation (ECMO), emphasizing the mechanisms underlying the dual risk of bleeding and..

Perfusfind S.L.

Abstract Background Extracorporeal cardiopulmonary resuscitation (ECPR), involving VA-ECMO during refractory cardiac arrest, has been linked to improved outcomes. While systemic anticoagulation is commonly used to prevent circuit thrombosis, bleeding and..

Perfusfind S.L.

Abstract In clinical extracorporeal membrane oxygenation (ECMO), prolonged blood residence time in oxygenators can lead to thrombus formation and complications. Heparin-based bioactive coatings are commonly used for anticoagulation, but prolonged..

Perfusfind S.L.

Abstract Background:  Compared to heparin, there is limited evidence of the benefits of bivalirudin in the patients with extracorporeal membrane oxygenation (ECMO). Methods:  We searched for studies comparing bivalirudin anticoagulation..

Perfusfind S.L.

Abstract The advancement of  has introduced a new dimension to managing patients who do not respond to conventional treatment of severe .  (ECMO) is a specialized temporary life support that serves as a..

Perfusfind S.L.

Abstract Solutions to reduce the need for systemic anticoagulation during extracorporeal life support would improve safety and utility. The study objective was to evaluate the safety and efficacy of a..

Perfusfind S.L.

Abstract Objective To review and compare the frequency of thrombus and adverse events in patients treated with heparin or bivalirudin systemic anticoagulation strategies supported on combined venoarterial extracorporeal membrane oxygenation..

Perfusfind S.L.

Abstract Background Extracorporeal membrane oxygenation (ECMO) is increasingly used in patients after cardiac surgery; however, anticoagulation management has consistently been challenging. This study aimed to explore the feasibility of a..

Perfusfind S.L.

Abstract Background Anticoagulation in pediatric extracorporeal membrane oxygenation (ECMO) presents unique challenges due to developmental hemostasis, coagulation factor production, and response to anticoagulants. This process requires close monitoring to prevent..

Perfusfind S.L.

Abstract Background Bleeding is a common and sometimes fatal complication of venovenous extracorporeal membrane oxygenation (ECMO). Whether lowering the intensity of anticoagulation during venovenous ECMO is safe or effective is..

Perfusfind S.L.

Abstract The 2021 Adult and Pediatric Anticoagulation Guidelines for patients on extracorporeal membrane oxygenation (ECMO) recommend a target partial thromboplastin time (PTT) between 60 and 85 seconds when unfractionated heparin..

Perfusfind S.L.

Abstract Introduction During extracorporeal membrane oxygenation (ECMO) systemic anticoagulation with unfractionated heparin (UFH) is standard-of-care. However, there is uncertainty regarding optimal anticoagulation monitoring strategies. Methods We retrospectively investigated venovenous and..

Perfusfind S.L.

Cardiopulmonary bypass (CPB) is a cornerstone of modern cardiac surgery, enabling complex procedures by temporarily taking over the heart and lung functions. However, one of the most critical aspects of..

Perfusfind S.L.

Abstract Background Patients with severe acute respiratory distress syndrome (ARDS) show a high mortality rate of up to 60 %. In such cases, extracorporeal membrane oxygenation (ECMO) support is often required,..

Perfusfind S.L.

Abstract Extracorporeal membrane oxygenation in a venovenous configuration (VV-ECMO) is increasingly recognized as an important therapeutic option for patients with severe acute respiratory distress syndrome (ARDS). Accumulating scientific evidence as well..

Perfusfind S.L.

Abstract Anticoagulation is an essential component of optimal extracorporeal membrane oxygenation (ECMO) management. Unfractionated heparin is still the anticoagulant of choice in most centers due to longstanding familiarity with the..

Perfusfind S.L.

Abstract Objective Extracorporeal membrane oxygenation (ECMO) requires systemic anticoagulation to reduce the risk of thromboembolic events. Despite its historic role, activated clotting time (ACT) remains a widely used heparin monitoring..

Perfusfind S.L.

Abstract The safe use of cardiopulmonary bypass (CPB) relies upon the ability to administer, monitor, and reverse anticoagulation. Although rare, the factor XII deficient patient creates a challenge for the..